The Hong Kong International Biotechnology Forum and Exhibition (BIOHK2023), organized by the Hong Kong Biotechnology Organization, was successfully held at the Hong Kong Convention and Exhibition Centre (HKCEC) on 13-16 September 2023. It is one of Asia’s largest international biotechnology conventions which aims to facilitate the exchange of ideas among international industry players and foster biotechnology innovation in Hong Kong. Lee's Pharmaceutical (HK) Limited ("Lee's Pharm" or the "Group", HKEx:00950), as a Silver Sponsor, continued to support the event and was honored with the "Best Pharmaceutical Company of the Year Award".

The Department of Economy and Information Technology of Anhui Province recently announced the first batch of the list of Innovative Small and Medium-sized Enterprises (SMEs) for 2023. After several rounds of selection, Zhaoke Pharmaceutical (Hefei) Company Limited ("Zhaoke-Hefei"), a subsidiary of Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Group", HKEx:00950), was successfully recognized as an innovative SME, and became a part of the gradient cultivation system for high-quality SMEs in Anhui Province.

Dr. Li Xiaoyi, the founder of Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or "the Group", HKEx:00950), was recently interviewed by Guangdong New Focus, a TV program of Guangdong Radio and Television, in which he explained the Group’s key to success since its establishment was “Focus, Innovation and Excellence”. Please click on the video below to watch the full interview.

June 28, 2023, the award ceremony of the 1st Greater Bay Area Excellent ESG Enterprise Election was held in Guangzhou, which was guided by Guangdong Federation of Industry and Commerce and co-organized by Guangdong Xinkuaibao Agency and Protron Consulting Group. After preliminary professional rating and public voting, Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or "the Group", HKEx:00950) was honored with the "Most Popular (ESG) Enterprise Award in the Greater Bay Area".

The 2023 China Medical and Health Industry Symbiosis Conference, organized by Menet, a healthcare information platform, was grandly held in Huzhou from 27 to 30 July, 2023. A number of lists were released during the conference, including the “China Pharmaceutical Industry Top 100 Series List” and the “Most Valuable Product in Partnership for Drug Store Chain”.

May 23, 2023, the Provincial Center for ADR Monitoring and the Provincial Medical Products Administration visited Zhaoke Pharmaceutical (Hefei) Company Limited ("Zhaoke Hefei"), a subsidiary of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950), to conduct on-site assessment. More than 10 pharmaceutical enterprises in Hefei were also invited, including representative enterprises which manufacture drugs selected for VBP, biological medicinal products and Chinese medicine preparations.

May 13, 2023, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) successfully held The 8th Pulmonary Arterial Hypertension Summit in Chongqing. With the theme of “Protecting Heart and Lungs For Health”, the forum aimed to promote academic exchanges at home and abroad, and to improve the diagnosis and treatment of pulmonary arterial hypertension.

May 9, 2023, the high-profile 86th PharmChina was grandly opened at the Qingdao International Expo Center on the theme "Building a new innovative and inclusive ecology of pharmaceutical and health". Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) participated in the event.

April 24, 2023, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950) announced that its in-licensed product Natulan® (Procarbazine Hydrochloride Capsules, formerly known as Procarbazine), was successfully launched in China and was distributed from its Guangzhou Nansha manufacturing site across the country.

Recently, the Guangdong High-tech Association granted the certificates of “Guangdong Famous High-tech Products” for 2022. The Sodium Phenylbutyrate Granules, an in-house developed product of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950), won the award by virtue of its outstanding innovation capacity, advanced technology, reliable quality and good market prospect.

Recently, Southern Metropolis Daily interviewed Dr. LI Xiao Yi Benjamin, the Founder and Director of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950), to discuss the current situation of domestic ophthalmic disease treatment and drug market.

On March 29, 2023, the preliminary bidding result of the eighth round of the national drug bulk-buying launched by the National Healthcare Security Administration was released. Zhaoke Pharmaceutical (Hefei) Company Limited, a subsidiary of Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or “the Group”, HKEx:00950), participated in the bidding and its product Nadroparin Calcium Injection won the bid as a generic drug approved under the new Registration Classification of Chemical Drugs. This is another product following Fondaparinux Sodium Injection that was selected in the government’s centralized medical procurement program.